RxDoctor Payments Data

Timothy Mercer, PA

Physician Assistant · Utica, NYNPI 1184668675

Payments from drug & device makers

$4,907in general payments, 2019–2025

Across 220 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$844
  • Actelion Pharmaceuticals US, Inc.$360
  • Sanofi$338
  • Electromed, Inc.$288
  • Boehringer Ingelheim$268
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,63895%
  • Education$2695%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,907 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$9,750
Medicare patients
80
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$104,919
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$23,865
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$19,447
Breo ElliptaFluticasone/Vilanterol15$9,934
SymbicortBudesonide/Formoterol Fumarate20$6,545
Albuterol Sulfate HfaAlbuterol Sulfate89$3,761
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,678
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,755
Azithromycin36$443
Montelukast Sodium36$374
Prednisone38$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$844$138,718145 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,321$25,99339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →